What Is 19-Nortestosterone 17β-pelargonate

Overview

19-Nortestosterone 17β-pelargonate is a synthetic derivative of nandrolone (19-nortestosterone), modified by the addition of a pelargonic acid ester at the 17β-hydroxyl group. This modification is designed to slow metabolism and extend the compound’s duration of action in the body, similar to other long-acting steroid esters like nandrolone decanoate.

First developed in the mid-20th century during the peak of anabolic steroid research, this compound never advanced beyond experimental stages. Despite structural similarities to approved anabolic agents, it has not been commercialized or used clinically due to limited efficacy and pharmacokinetic challenges.

• Synthesis date: First prepared in 1957 during early steroid esterification studies at pharmaceutical research labs in Europe.
• Chemical class: It belongs to the 19-norandrostane family, sharing core structure with nandrolone and trenbolone.
• Molecular weight: The compound has a molecular weight of 402.58 g/mol, reflecting its C27H42O3 formula.
• Ester chain: The pelargonic acid (C9) ester increases lipophilicity, potentially extending half-life in muscle tissue.
• Research status: Remains an unmarketed experimental compound with no FDA or EMA approval.

How It Works

The mechanism of action of 19-nortestosterone derivatives involves binding to androgen receptors in muscle and bone tissues, promoting protein synthesis and anabolic effects. The pelargonate ester slows release from injection sites and delays hepatic breakdown, aiming for sustained activity.

• Androgen receptor binding: The parent compound, nandrolone, binds to androgen receptors with affinity of ~30% compared to testosterone.
• Ester hydrolysis: Enzymatic cleavage in blood releases free nandrolone over 3–5 days post-injection.
• Anabolic ratio: Estimated at 120:30 (anabolic:androgenic), lower than nandrolone decanoate.
• Hepatic metabolism: Undergoes reduction in the liver, forming inactive metabolites excreted in urine.
• Half-life: The pelargonate ester extends half-life to approximately 72 hours, shorter than decanoate analogs.
• Prodrug nature: Acts as a prodrug, requiring in vivo hydrolysis to exert biological activity.

Comparison at a Glance

Below is a comparison of 19-Nortestosterone 17β-pelargonate with related compounds in terms of structure, potency, and pharmacokinetics:

While structurally similar to approved nandrolone esters, the pelargonate version offers no pharmacokinetic advantages. Its shorter half-life and lack of clinical data contributed to its abandonment in favor of longer-acting alternatives like decanoate. The table illustrates how minor changes in ester length significantly impact duration and utility.

Why It Matters

Though not a commercial drug, 19-Nortestosterone 17β-pelargonate contributes to understanding structure-activity relationships in steroid design. Researchers use such analogs to explore how ester length influences bioavailability and metabolic stability.

• Historical significance: Represents mid-20th century efforts to optimize anabolic steroid half-life through ester modification.
• Pharmacological insight: Demonstrates that C9 esters do not always confer longer action than C8–C10 chains.
• Drug development: Informs modern prodrug design for androgen replacement therapies and tissue-selective anabolics.
• Forensic relevance: May appear in doping control assays as a metabolite of nandrolone if misused.
• Regulatory status: Not scheduled under the Controlled Substances Act but falls under anabolic steroid regulations if distributed.
• Research utility: Serves as a reference compound in steroid metabolism studies and receptor binding assays.

Understanding obscure analogs like this helps clarify why certain esters succeeded while others faded into scientific footnotes. It underscores the precision required in pharmaceutical development and the importance of pharmacokinetic optimization.